Charles River Laboratories International, Inc. — Cyborg Score 6/10
Solid
Contract Research Organizations (CRO) / Contract Development and Manufacturing Organizations (CDMO)
Strategic Profile
Charles River is committed to remaining a leader in regulatory required drug development solutions by pairing the best traditional testing methods to ensure patient safety with scientific advancements and innovative solutions to drive greater efficiency and success in clients' drug development programs. The company is executing strategic acquisitions to vertically integrate supply chains and enhance advanced testing capabilities.
Cyborg Score Rationale
Demand trends for the company's Discovery and Safety Assessment (DSA) business have continued to improve throughout the second half of 2025, resulting in a preliminary estimate for the DSA net book-to-bill of approximately 1.1x in the fourth quarter of 2025. Foreign exchange is expected to add 100–150 basis points to reported revenue growth, and incremental cost savings of more than $100M in 2026 are intended to offset cost inflation and support non-GAAP operating margin.
Top Insights
DSA segment demand improved throughout H2 2025 with book-to-bill of 1.1x in Q4 2025, indicating recovery momentum
Two strategic acquisitions announced: K.F. (Cambodia) Ltd. and PathoQuest SAS, plus appointment of new Chief Scientific and Innovation Officer
Guidance for 2026 expects organic revenue growth at top end to be at least flat, with cautious expectation of returning to growth in H2 2026
Cost savings program targeting >$100M in 2026 to offset inflation and support margin expansion amid challenging revenue environment
Named Competitors
Parexel — Global clinical research and consulting services for life sciences
ICON — Contract research organization for clinical and pharmaceutical development
Labcorp Drug Development — Drug development and nonclinical testing services
Eurofins Scientific — Testing services for pharmaceutical and biotech development
Recent Developments
(January 2026) Announced acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS plus appointment of Dr. Namandjé N. Bumpus as Chief Scientific and Innovation Officer
(January 2026) Provided preliminary 2026 guidance showing DSA demand improvement with >$100M cost savings program and expectation of return to organic growth in H2 2026
(February 2026) Scheduled Q4 2025 earnings and 2026 guidance release for February 18, 2026
Open the full interactive Charles River Laboratories International, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.